Nouscom, a clinical stage immuno-oncology company developing off-the-shelf and personalized viral vector-based cancer vaccines targeting neoantigens, has announced the completion of its oversubscribed Series C equity financing raising EUR 67.5m (USD 72m) from a syndicate of re-nowned international healthcare investors.
The Series C round was co-led by Andera Partners, Bpifrance (through its InnoBio 2 fund) and M Ventures, with participation from Revelation Partners, Indaco Venture Partners, Panakès Part-ners, XGen Ventures, and other undisclosed investors together with continued support from exist-ing investors 5AM Ventures, EQT Life Sciences and Versant Ventures. The proceeds will be used to continue advancing and expanding Nouscom’s wholly owned clinical pipeline.
VISCHER acted as legal advisor to Nouscom in the transaction. The team includes partner Matthias Staehelin (corporate / M&A, pictured), managing associate Adrian Briner (tax), senior associate Pauline Pfirter and managing associate Luzius Zumstein (both corporate / M&A).